PATENT CLAIM ANALYSIS

Application Number: 15774978
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "450000"]

Abstract:
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

Claim (Index 41):
The method of  claim 40 , wherein the hematologic cancer is selected from the group consisting of acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPNs) and lymphomas.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.26667
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15715274', '14053011', '15195297', '14703500', '14212418']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7734224485614656
- 35 USC 102 Novelty (BERT): 0.4880981414420669
- Combined Prediction Score: 0.7448900178495258
- Mean Citation Score: 231.841468
- Max Citation Score: 239.94547000000003
- Similarity Product: 194.0907033078844

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test